Simple Blood Ratio Shows Promise for Spotting Aggressive Kidney and Ureter Cancer Before Surgery

Every year, thousands of patients diagnosed with cancer of the renal pelvis or ureter face a deeply uncomfortable uncertainty. Upper tract urothelial carcinoma, a malignancy arising from the same lining that gives rise to bladder cancer, is notoriously difficult to stage before an operation. Surgeons must decide whether to remove a kidney and its entire draining ureter without ever knowing for certain whether the tumor has already invaded the muscular wall of the collecting system or pushed beyond it into surrounding tissue. A new study from Sichuan Provincial People’s Hospital in Chengdu, China, published in BMC Cancer, suggests that part of the answer may already be sitting in a routine blood sample drawn before surgery, in the form of a simple ratio between two familiar proteins: fibrinogen and albumin.

The clinical problem the researchers set out to address is one of the most stubborn in urologic oncology. Current preoperative staging of upper tract urothelial carcinoma relies on cross-sectional imaging, such as computed tomography urography, and on ureteroscopic biopsy, in which a thin scope is threaded up the ureter to sample the tumor directly. Both tools have recognized limitations when it comes to predicting muscle invasion. Imaging can underestimate how deeply a tumor has grown, and ureteroscopic biopsies are often small, frequently non-diagnostic, and prone to undergrading the tumor’s true aggressiveness. Because the presence of muscle-invasive disease changes everything about treatment, including whether chemotherapy should be given before surgery, an accurate preoperative estimate of invasion risk carries real consequences for patients.

The team, led by Guopeng Wang together with senior and corresponding authors Dong Wang, Yu Mao and Shangqing Ren, focused on the fibrinogen-to-albumin ratio, or FAR, one of a family of so-called inflammation–nutrition indices that can be calculated from standard blood tests. The biological rationale is straightforward. Fibrinogen, the clotting protein, rises in response to systemic inflammation, and chronic inflammation is closely intertwined with tumor progression, invasion, and metastasis. Albumin, the most abundant blood protein, falls when the body is under inflammatory or nutritional stress. Dividing one by the other yields a single number that integrates both signals, rising when inflammation is high and nutritional reserve is low, a combination that in many cancers tracks with more aggressive biology.

To test whether FAR actually carries staging information, the researchers retrospectively analyzed 127 patients with upper tract urothelial carcinoma who underwent robot-assisted radical nephroureterectomy between 2018 and 2025. All patients had complete preoperative blood counts and biochemistry, and every tumor was staged definitively by pathologic examination after surgery. The disease burden in this cohort was substantial: 76.4 percent of patients turned out to have muscle-invasive disease, defined as pathologic stage pT2 or higher, and 40.2 percent had locally advanced tumors invading beyond the organ wall, stages pT3 to pT4. The researchers compared FAR against four other widely used indices computed from blood counts: the neutrophil-to-lymphocyte ratio, the platelet-to-lymphocyte ratio, the lymphocyte-to-monocyte ratio, and the systemic immune-inflammation index.

The head-to-head comparison produced a nuanced result. FAR showed the numerically highest discrimination among the five indices, with an area under the receiver operating characteristic curve of 0.631 for predicting muscle-invasive disease and 0.611 for predicting locally advanced disease. Those values indicate modest predictive power, better than a coin flip but far from definitive. More importantly, the authors were careful to note that FAR was not statistically superior to any of the other four indices. In other words, the apparent edge could plausibly reflect chance in a cohort of this size, and the honest conclusion is that FAR performs at least as well as its competitors rather than clearly better than them.

Where the analysis became more interesting was in the multivariable modeling. After adjusting for other clinical factors, FAR remained an independent predictor of both endpoints. Each 0.01 increase in the ratio was associated with an adjusted odds ratio of 1.15 for muscle-invasive disease, with a 95 percent confidence interval of 1.00 to 1.32, and an adjusted odds ratio of 1.13 for locally advanced disease, with a confidence interval of 1.02 to 1.26. The researchers then built a combined nomogram, a graphical scoring tool that clinicians can use at the bedside, incorporating FAR together with four routinely available variables: patient sex, tumor location, estimated glomerular filtration rate, and diabetes status. This combined model raised the area under the curve from 0.699 to 0.745 for muscle invasion and from 0.697 to 0.728 for locally advanced disease.

Notably, the authors resisted the temptation to oversell that improvement. The gains in discrimination did not reach statistical significance, with DeLong test P values of 0.154 and 0.287 for the two endpoints. However, several complementary performance measures moved in a supportive direction. Reclassification metrics, the net reclassification improvement and integrated discrimination improvement, suggested the combined model sorted patients into risk categories more accurately. Calibration, the agreement between predicted and observed probabilities, was favorable, and decision-curve analysis, which estimates the net clinical benefit of acting on a model’s predictions across a range of risk thresholds, also favored the combined tool. The authors explicitly characterized this added contribution of FAR as exploratory and preliminary, a level of caution that is refreshingly rare in biomarker research.

The study also employed a validation strategy more rigorous than most single-center biomarker papers attempt. Rather than relying on a random split, the team performed internal temporal validation, developing the model on patients treated from 2018 to 2022, a group of 83 individuals, and testing it on those treated from 2023 to 2025, a group of 44. This design simulates how a model behaves on future patients, who may differ in case mix from earlier cohorts. The combined model held up reasonably well, achieving an area under the curve of 0.703 for muscle-invasive disease and 0.741 for locally advanced disease in the temporal validation set. The confidence intervals, however, were wide, spanning roughly 0.53 to 0.85 and 0.59 to 0.87 respectively, a reminder that 44 validation patients cannot pin down performance precisely. The team additionally applied bootstrap optimism correction and case-mix re-weighting, and used a Firth penalized-likelihood sensitivity analysis to guard against instability from the limited number of predictor variables relative to events.

Perhaps the most scientifically valuable part of the paper is what the authors admit the study cannot show. Their reference model did not include biopsy grade, hydronephrosis, or radiological evidence of invasion, the very features that make up contemporary upper tract urothelial carcinoma risk-assessment tools. Because those established predictors were absent from the comparison, the data cannot establish whether FAR adds information beyond what urologists already use. The study also did not specifically evaluate patients in whom ureteroscopic biopsy failed or returned non-diagnostic results, the population that would arguably benefit most from an alternative risk signal. The authors therefore position the nomogram not as a replacement for biopsy and imaging but as a complementary, rule-out-oriented adjunct, one input among several in preoperative multidisciplinary assessment, potentially useful for flagging patients at low risk of muscle invasion.

The practical appeal of the approach is undeniable. FAR requires nothing beyond a preoperative blood sample that virtually every surgical patient already provides, no additional cost, no specialized equipment, and no new testing. If future work confirms its value, it could serve as an inexpensive early flag that prompts more intensive imaging review, a repeat biopsy attempt, or consideration of neoadjuvant chemotherapy in borderline cases. But the path from a single-center retrospective cohort of 127 patients to routine clinical use is long, and the authors are unambiguous that multicenter external validation is required before any clinical application. For now, the study stands as a careful, methodologically transparent demonstration that the inflammatory fingerprint visible in routine blood work carries genuine, if modest, information about how dangerous a kidney and ureter tumor may be, and as a model of how biomarker research should be reported, with its limitations stated as plainly as its promise.

Subject of Research: Preoperative prediction of muscle-invasive and locally advanced upper tract urothelial carcinoma using the fibrinogen-to-albumin ratio

Article Title: Preoperative fibrinogen-to-albumin ratio and prediction of muscle-invasive and locally advanced upper tract urothelial carcinoma: development and internal temporal validation of a nomogram

Article References: Wang, G., Dong, X., Zhang, X., Gu, C., Hu, T., Yang, F., Wang, D., Mao, Y., & Ren, S. (2026). Preoperative fibrinogen-to-albumin ratio and prediction of muscle-invasive and locally advanced upper tract urothelial carcinoma: development and internal temporal validation of a nomogram. BMC Cancer. https://doi.org/10.1186/s12885-026-17104-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17104-w

Keywords: upper tract urothelial carcinoma, fibrinogen-to-albumin ratio, nomogram, muscle-invasive disease, locally advanced disease, preoperative staging, inflammation-nutrition indices, radical nephroureterectomy, biomarkers, decision-curve analysis, internal temporal validation, robot-assisted surgery